Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 03:35:55 17/01/26 am AEDT			5-day change	1st Jan Change
41.52 ^EUR	-1.38%		+6.78%	+12.17%

09:49pm	Bayer Receives EU Approval for High-Dose Eylea in Another Indication	DP
17/01	Health Care Up as Wegovy Pill Buoys Novo Nordisk -- Health Care Roundup	DJ

BAYER AG : Berenberg reiterates its Neutral rating

Published on 12/12/2025 at 06:15 pm AEDT

MarketScreener with dpa-AFX Analyser

Bayer AG

-1.38%

In his latest research note, analyst Sebastian Bray confirms his recommendation. The broker Berenberg is keeping its Neutral rating. The target price has been lifted and is now set at EUR 41 compared to EUR 30.40 before.

Latest news about Bayer AG

09:49pm	Bayer Receives EU Approval for High-Dose Eylea in Another Indication	DP
17/01	Health Care Up as Wegovy Pill Buoys Novo Nordisk -- Health Care Roundup	DJ
17/01	Bayer welcomes US Supreme Court decision to review Durnell case in Roundup litigation	RE
17/01	Bayer AG - Company expects a decision on merits during court's 2026 session, which ends in June	RE
17/01	Bayer AG - U.S. Supreme Court today announced that it will review Durnell Roundup case	RE
17/01	US Supreme Court to hear Bayer's bid to curb Roundup cases	RE
17/01	U.S. Supreme Court agrees to hear Bayer's bid to limit lawsuits filed under state laws over its weedkiller Roundup	RE
17/01	Bayer's Eylea Secures EU Approval for Retinal Vein Occlusion	MT
16/01	MWB Research Upgrades Bayer to Buy, Boosts PT	MT
16/01	Bayer Receives EU Approval for High-Dose Eylea in Another Indication	DP
16/01	Bayer says Eylea 8 mg approved in the EU for third retinal indication	RE
16/01	BAYER AG : UBS sticks Neutral	ZD
16/01	Dax Expected to Open Lower – Inflation and Auto Sector in Focus	RE
16/01	Bayer Upgraded to Buy as mwb Notes 'Improving Medium-term Risk-Reward'	MT
15/01	European Midday Briefing : Shares Rise; Gold and Oil Fall on Easing U.S.-Iran Tensions	DJ
15/01	German DAX Index Slips; Bayer, RWE Shares Surge	MT
15/01	Frankfurt Stocks Close: DAX Ends Impressive Record-Breaking Streak	DP
15/01	Orion Sees Long-Term Nubeqa Sales Surpassing 1 Billion Euros – Issues 2026 Forecast (Update)	FW
15/01	Orion Estimates to Hit Annual Net Sales Target for Nubeqa by Decade-end	MT
15/01	Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug	DJ
14/01	Bayer Continues Recovery Rally – Sees Major Pharma Potential Ahead	DP
14/01	Ipsen and EMS-Chemie Shine on the Stock Market, Vistry and Pearson Struggle
14/01	Bayer Sees Pharmaceutical Business on Growth Trajectory	DP
14/01	U.S. Futures Fall, Precious Metals Gain on Iranian Unrest	DJ
14/01	Historic Morning Record for the CAC 40

Chart Bayer AG

Duration

Period

BAYN: Dynamic Chart

Company Profile

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.6%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.2%), Switzerland (1.2%), Europe/Middle East/Africa (23.6%), the United States (31.7%), North America (3.6%), China (7.7%), Asia/Pacific (9.6%), Brazil (9.3%) and Latin America (8.1%).

Employees

88,502

Sector

Pharmaceuticals

Calendar

19/01 - Kepler Cheuvreux German Corporate Conference

More about the company